Investor Relations

Nuvalent is creating precisely targeted therapies designed to overcome the limitations of existing therapies for clinically proven kinase targets for patients with cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.

Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.

View Corporate Presentation

Stock Information
Latest News & Events
May 12, 2022

Two clinical-stage programs ongoing for potential best-in-class ROS1 and ALK-selective inhibitors On-track for selection of two additional development candidates in 2022 Ended the first quarter of...

Apr 8, 2022

NVL-520 showed strong preclinical activity against diverse ROS1 fusion partners and kinase-domain resistance mutations, as well as in a ROS1-driven model of glioblastoma NVL-655 demonstrated...

Apr 7, 2022

Nuvalent, Inc. (NASDAQ: NUVL), a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that...

See All